Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Novacyt    ALNOV   FR0010397232


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt S.A.: Executive Management and Proposed Board Changes

01/05/2021 | 02:01am EDT

Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt" or the "Company" or the "Group"), an international specialist in clinical diagnostics, announces that James McCarthy has been appointed as Chief Financial Officer (CFO), whilst Anthony Dyer has taken on a new role as Chief Corporate Development Officer (CCDO). Both appointments are with immediate effect.

Mr McCarthy will become a Board Director of the Company, subject to shareholder approval, at the AGM. Anthony Dyer will remain a Board Director until James McCarthy is elected to the Board.

James has held a number of senior positions in major listed and private equity-backed businesses. Most recently he was CFO of Flint Group, a $2.5bn revenue, PE backed business with 7,900 staff and 180 sites across 40 countries. Previously, he was CFO of Brambles Plc’s EMEA CHEP business before being promoted to President of CHEP’s European team. Brambles Plc is an Australian-based, ASX listed business with a market capitalisation of AU$16bn. James trained as an accountant with Dairygold, receiving his ACCA qualification in 1988, before going on to work for a range of businesses including Unilever and ICI Plc.

Graham Mullis, Chief Executive Officer of Novacyt, commented:
"On behalf of the Board, I am pleased to welcome James to the role of CFO. He joins Novacyt having held senior finance positions at a number of large blue-chip manufacturing organisations. His considerable financial, commercial and Board experience will be invaluable as Novacyt embarks on its next stage of growth.

“I would also like to take this opportunity to thank Anthony personally for the key role he has played in helping transform Novacyt into a leading diagnostics developer and manufacturer. His new, important role reflects the Company’s growth strategy, which includes selective potential M&A to supplement organic growth initiatives. I look forward to working with Anthony and James as part of an expanded executive team.”

The information required by Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in relation to the appointment of James Martin McCarthy (age 54) is as follows:

Current directorships


Past directorships held within last five years

Energy Transition Forum Limited


CHEP Israel Limited

Focus4Value Limited


Xeikon NV.




Mr McCarthy holds 10,000 ordinary shares in the Company. There are no other disclosures required in accordance with Schedule 2(g) of the AIM Rules.

About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

© Business Wire 2021
All news about NOVACYT
03/24NOVACYT  : to Launch Test For COVID-19 Variants of Concern
03/24NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of CE-Mark test to detect multiple..
03/17NOVACYT  : Launches Mobile Processing Laboratories For On-Site Rapid COVID-19 Te..
03/17NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of Mobile Processing Laboratories ..
02/24NOVACYT S.A. :  Research and Development Update
02/02NOVACYT  : Launches New Tests to Diagnose Latest COVID-19 Variants; Shares Rise ..
02/02NOVACYT  : Rolls Out New Product For Detection Of COVID-19 Variants
02/02NOVACYT S.A. :  Launch of PCR Genotyping Assay Portfolio to Detect COVID-19 Vari..
01/29NOVACYT  : FY20 Revenue Soars 20x On COVID-19 Product Sales; Shares Down 6%
01/29NOVACYT S.A. : Full Year 2020 Trading Update
More news
Sales 2020 312 M 371 M 371 M
Net income 2020 183 M 217 M 217 M
Net cash 2020 41,3 M 49,2 M 49,2 M
P/E ratio 2020 2,03x
Yield 2020 -
Capitalization 330 M 393 M 393 M
EV / Sales 2020 0,93x
EV / Sales 2021 1,38x
Nbr of Employees 110
Free-Float 99,3%
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 4,67 €
Spread / Highest target 22,0%
Spread / Average Target 4,88%
Spread / Lowest Target -12,2%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Lisa Henriet Director-Group Operations
Andrew John William Heath Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.34.89%56 442
WUXI APPTEC CO., LTD.-1.48%45 479